1. Klein R. Retinopathy in a population-based study. Trans Am Ophthalmol Soc. 1992; 90:561–94.
2. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS Report No.12. Ophthalmology. 1991; 98:823–33.
3. Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study (DRS): DRS report No. 8. Ophthalmology. 1981; 88:583–600.
4. Flynn HW Jr, Chew EY, Simons BD, et al. Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS Report No. 17. Ophthalmology. 1992; 99:1351–7.
5. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS Report No. 9. Ophthalmology. 1991; 98:766–85.
6. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994; 331:1480–7.
Article
7. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994; 118:445–50.
Article
8. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischaemia associated iris neo-vascularization in a non-human primate. Arch Ophthalmol. 1996; 114:66–71.
9. Cunningham ET Jr, Adamis AP, Altaweel M, et al. A phase II randomized doublemasked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005; 112:1747–57.
Article
10. Chun DW, Heier JS, Topping TM, Duker JS & Bankert JM. Pilot study of multiple intravitreal injections of ranibizumab in patients with centre-involving clinically significant diabetic macular edema. Ophthalmology. 2006; 113:1707–12.
11. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina. 2006; 26:352–4.
Article
12. Spaide RF & Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous haemorrhage. Retina. 2006; 26:275–8.
13. Jorge R, Costa RA, Calucci D, et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE Study). Retina. 2006; 26:1006–13.
Article
14. Cho WB, Oh SB, Moon JW, et al. Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy. Retina. 2009; 29:516–22.
Article
15. Chang JK, Chang MH. Therapeutic Effects of Intravitreal Bevacizumab Injection for Retinal Neovascularization Secondary to Proliferative Diabetic Retinopathy. J Korean Ophthalmol Soc. 2009; 50:1359–70.
Article
16. McDonald HR, Schatz H. Macular edema following panretinal photocoagulation. Retina. 1985; 5:5–10.
Article
17. McDonald HR, Schatz H. Visual loss following panretinal photo-coagulation for proliferative diabetic retinopathy. Ophthalmology. 1985; 92:388–93.
Article
18. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology. 1991; 98:766–85.
19. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002; 109:920–7.
Article
20. Choi KS, Chung JK, Lim SH. Laser Photocoagulation Combined with Intravitreal Triamcinolone Acetonide Injection in Proliferative Diabetic Retinopathy with Macular Edema. Korean J Ophthalmology. 2007; 21:11–7.
Article
21. Jonas JB, Degenring R, Kreissig I, et al. Safety ofintravitreal high-dose reinjections of triamcinolone acetonide. Am J Ophthalmol. 2004; 138:1054–5.
22. Gillies MC, Simpson JM, Billson FA, et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol. 2004; 122:336–40.
23. Nonaka A, Kiryu J, Tsujikawa A, et al. Inflammatory response after scatter laser photocoagulation in nonphotocoagulated retina. Invest Ophthalmol Vis Sci. 2002; 43:1204–9.
24. Brooks HL Jr, Caballero S Jr, Newell CK, et al. Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. Arch Ophthalmol. 2004; 122:1801–7.
25. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina. 2006; 26:999–1005.
Article
26. Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, et al. For the Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab: Results of the PACORES. Graefes Arch Clin Exp Ophthalmol. 2008; 246:81–7.
27. Shima C, Sakaguchi H, Gomi F, et al. Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol. 2008; 86:372–6.
Article